Thymalin Dosage Guide: Protocols, Calculator & Safety
Everything you need to know about Thymalin dosing — protocols, safety, and where to buy.
Dosage Calculator
Calculate exact dosing for Thymalin.
Dosing Protocols
Beginner protocol (first-time Thymalin user, research-chemical context).
- Dose: 5-10 mg/day intramuscular or subcutaneous injection
- Duration: 10 consecutive days per course
- Courses per year: 1-2 (typically biannual, one in early spring and one in autumn to support immune function through seasonal transitions)
- Route: Intramuscular (preferred per Russian clinical protocols; deltoid or gluteal injection) or subcutaneous (abdomen or thigh; easier for self-administration but slightly different pharmacokinetics)
- Reconstitution: Reconstitute lyophilized Thymalin in bacteriostatic water or sterile saline per vial instructions (typically 1-2 mL per 10 mg vial); use within 7 days refrigerated after reconstitution
- Administration timing: Morning dosing preferred to align with circadian cortisol and immune rhythms; on an empty stomach or separated from meals by 30+ minutes
- Monitoring: Complete blood count with lymphocyte differential at baseline and end of course; optional T-cell subset panel (CD4, CD8, CD4:CD8 ratio, naive:memory ratios) at baseline and 1 month post-course for more detailed tracking
- Expected effects: Subjective improvements in energy, reduced frequency of minor infections, improved recovery from physical activity; objective changes in T-cell panels over 1-6 month timeframe
First-time users should start at the lower end (5 mg/day) for the first course to assess tolerability, then escalate to 10 mg/day for subsequent courses if well-tolerated. The beginner protocol reflects the lowest-risk reasonable starting point from the Russian clinical standard.
Intermediate protocol (established Thymalin user, clear rationale, integrated use).
- Dose: 10 mg/day intramuscular or subcutaneous injection
- Duration: 10 consecutive days per course
- Courses per year: 2-3 depending on baseline immune status and clinical context
- Canonical Khavinson combination: Alternate 10-day Thymalin courses with 10-day Epithalon courses (5-10 mg/day subcutaneously), separated by 2-4 weeks between different peptide courses, with the combined cycle repeated biannually
- Integration with seasonal immune needs: Schedule one course in September-October (pre-flu-season immune support) and one in February-March (post-winter immune restoration). A third course may be added during periods of elevated immune demand (post-illness, post-surgery, periods of chronic stress)
- Integration with health optimization: Combine with vitamin D repletion, zinc adequacy, adequate protein intake, and sleep optimization for amplified effect
- Monitoring: CBC with lymphocyte differential and T-cell subset panel at baseline, end of course, and 3 months post-course; infection frequency tracking in personal health log; subjective immune status assessment
Targeted intermediate protocols by context:
- Post-infectious immune restoration (e.g., post-COVID, post-major viral illness): Single 10-day course at 10 mg/day starting 1-2 weeks after acute illness resolution; can be repeated 1-3 months later if recovery is incomplete
- Elderly immune support (age 65+): Biannual 10-day courses at 10 mg/day combined with Epithalon cycles; continue indefinitely as part of ongoing healthy-aging protocol
- Pre-surgical or pre-chemotherapy immune optimization: 10-day course completed 1-2 weeks before planned immune-suppressive intervention; repeat 2-4 weeks after intervention completion
- Chronic immune dysfunction context (e.g., long COVID, chronic fatigue syndrome with documented immune dysfunction): Quarterly 10-day courses at 10 mg/day; evaluate response after 2 cycles before committing to longer-term protocol
General intermediate-protocol principles:
- Standardize injection technique (sterile, subcutaneous or intramuscular, rotating sites)
- Refrigerate reconstituted product and use within appropriate window
- Track response with both subjective markers and available objective labs
- Do not escalate to daily continuous dosing — the 10-day-course protocol is evidence-based and continuous dosing is not the Russian clinical standard
- Source from suppliers with documented chain of custody; prefer Russian pharmaceutical product where accessible
Advanced protocol (experienced user, research context, combination protocols, elderly longevity focus).
- Dose: 10-15 mg/day intramuscular
- Duration: 10-14 consecutive days per course
- Frequency: Up to 3-4 courses per year
- Full Khavinson longevity stack (based on Russian clinical trials): Sequential 10-day courses of Thymalin (10 mg/day) followed 2 weeks later by Epithalon (5-10 mg/day), then 2 weeks later by other Khavinson peptides as indicated (Livagen for liver, Cartalax for joints, Bronchogen for respiratory health, etc.). Full annual cycle may involve 4-6 separate 10-day peptide courses
- Integration with comprehensive longevity protocol: Combine with Rapamycin cycling (if using), Metformin, NMN or NAD precursors, and lifestyle optimization (Zone 2 cardio, resistance training, protein intake 1.2-1.6 g/kg/day, circadian-aligned eating)
- Immune-marker-guided dosing: Use quarterly T-cell subset panels and inflammatory biomarkers (CRP, IL-6) to titrate course frequency — subjects with persistently depressed naive T-cell populations or elevated inflammatory markers may benefit from more frequent courses
- Combination with synthetic short peptides: Include Khavinson's synthetic tetrapeptides (Epithalon AEDG, Livagen KEDG, Cartalax AEDP, etc.) as individual components of a comprehensive tissue-specific peptide protocol
Advanced safety considerations:
- Higher cumulative dose exposure over years; source quality becomes critical
- Consider intermittent breaks (1-2 month gaps between cycles) to avoid diminishing returns from chronic signaling
- Track comprehensive biomarkers including inflammatory panels, T-cell subsets, and when available, biological age markers
- Work with a physician familiar with Russian peptide bioregulator tradition or functional medicine / longevity medicine practitioner
- Maintain pharmacy/supplier documentation for all products used
Contraindications for advanced protocols:
- Active autoimmune disease on immunosuppression (relative contraindication — proceed only with rheumatology guidance)
- Active malignancy outside of specific oncology-integrated protocols (relative contraindication — not a standalone cancer treatment)
- Transplant patients on immunosuppression (relative contraindication — discuss with transplant team)
- Known allergy to bovine products or peptide preparations (absolute contraindication)
- Pregnancy or breastfeeding (absolute contraindication due to absence of safety data)
Honest framing for advanced users: The advanced Thymalin protocols are extrapolations from Russian clinical tradition applied to Western research-chemical users. They are more elaborate than clearly necessary based on Russian primary evidence. The evidence-base-supported core is simple: 10 mg/day x 10 days, biannually, possibly with Epithalon alternation. Beyond that is experiment rather than established practice.
Commonly Stacked With
Thymalin stacks coherently with several other peptide and lifestyle interventions, with specific combinations reflecting the Khavinson clinical tradition from which Thymalin emerged and others reflecting Western research-peptide user preferences.
The canonical Khavinson stack: Thymalin + Epithalon. Epithalon is Khavinson's pineal tetrapeptide (Ala-Glu-Asp-Gly, AEDG) claimed to support telomerase activity and circadian rhythm restoration. The combination of Thymalin (immune) plus Epithalon (pineal) has been used in the longitudinal Russian elderly cohort trials and represents the most-studied Thymalin combination protocol. Standard administration alternates 10-day courses of each peptide separated by a few weeks, with cycles repeated biannually. The rationale is complementary organ-system restoration: thymus (immune) plus pineal (neuroendocrine and circadian) are both sites of substantial age-related dysfunction, and the combination may be more effective than either alone.
Thymalin + Thymosin Alpha-1. While Thymalin contains or overlaps with Thymosin Alpha-1, some protocols add synthetic pharmaceutical-grade Thymosin Alpha-1 on top of Thymalin to provide a defined, high-dose, single-peptide component alongside the mixture. This is a reasonable approach in research-chemical contexts where Thymalin quality is uncertain — the Thymosin Alpha-1 provides a known-dose component while the Thymalin provides the broader peptide mixture.
Thymalin + BPC-157 and TB-500. For post-surgical or post-injury immune and regenerative support, the combination of thymic peptide (Thymalin or Thymosin Alpha-1) plus gastric peptide (BPC-157) plus thymic beta-4 fragment (TB-500) forms a widely-used recovery stack in the research-peptide community. The rationale combines immune restoration (Thymalin) with tissue-specific regenerative signaling (BPC-157, TB-500). Evidence for the specific combination is limited but the individual components have independent supporting data.
Thymalin + GHK-Cu. The copper peptide GHK-Cu provides complementary anti-aging effects on connective tissue, skin, and hair while Thymalin focuses on immune function. The combination is a common "Khavinson plus Pickart" stack in longevity-focused protocols.
Thymalin + specific Khavinson short peptides. The Khavinson lab has developed specific synthetic short peptides corresponding to active fractions of different tissue extracts: Livagen (Lys-Glu-Asp-Gly, liver), Cartalax (Ala-Glu-Asp-Pro, cartilage), Pinealon (Glu-Asp-Arg, pineal neural), Bronchogen (Ala-Glu-Asp-Leu, bronchial), Cardiogen (Ala-Glu-Asp-Arg, cardiac), Ovagen (Glu-Asp-Leu, ovarian), and others. These are sometimes combined with Thymalin in organ-system-specific protocols, though the evidence for the individual short peptides is less substantial than for the original tissue-extract mixtures.
Thymalin + Vitamin D. Vitamin D has substantial independent effects on immune function (particularly T-cell and innate immune function), and adequate vitamin D status is a prerequisite for optimal immune response to any immunomodulatory intervention. Combination with vitamin D to achieve 25(OH)D levels of 40-60 ng/mL is often recommended in immune restoration protocols.
Thymalin + Zinc. Zinc is a critical cofactor for thymic function and T-cell maturation. Zinc deficiency is common in elderly populations and in chronically ill patients. Combination with zinc supplementation to achieve adequate status (typically 15-30 mg/day elemental zinc) is a reasonable adjunct for immune-restoration protocols.
Thymalin + NAC and Glutathione. For post-infectious recovery or aging-related oxidative stress contexts, combining Thymalin (immune restoration) with antioxidant support (NAC and/or glutathione) provides complementary mechanisms. The combination is mechanistically sensible though specific combination trial data are limited.
Potentially redundant or counterproductive combinations:
- Thymalin + Thymosin Beta-4 (TB-500) + Thymalin-derived short peptides all at once: risk of oversignaling the thymic/immune system without clear additive benefit. Simplify protocols.
- Thymalin + immunosuppressive medications: mechanism antagonism; if on immunosuppressants for transplant or autoimmune disease, discuss with specialist before adding Thymalin.
- Thymalin during active autoimmune flare: immune activation during active autoimmune disease may worsen symptoms; wait for stable disease state or use only under rheumatology or immunology guidance.
Lifestyle factors that amplify Thymalin effects:
- Adequate protein intake (cysteine, glycine, glutamate — GSH building blocks needed for immune cell function)
- Regular moderate exercise (enhances T-cell mobilization and naive T-cell output)
- Adequate sleep (sleep deprivation blunts immune restoration)
- Sun exposure or supplementation for vitamin D sufficiency
- Zinc-adequate diet (oysters, red meat, legumes) or supplementation
- Avoidance of chronic alcohol excess (thymus-suppressive)
- Stress management (chronic cortisol elevation suppresses thymic function)
Cycling protocols:
Standard Russian clinical protocols use Thymalin in discrete 10-day courses rather than continuous dosing, with 3-6 month intervals between courses and often alternating with Epithalon cycles. This intermittent dosing pattern may be more physiologically appropriate than continuous dosing because immune-system "reset" is the goal rather than chronic immune stimulation.
Side Effects & Safety
Contraindications
**Absolute contraindications:** - **Known hypersensitivity or allergic reaction to Thymalin or any thymic peptide preparation** — no further use. - **Known allergy to bovine products, bovine serum albumin, or documented severe beef allergy** — Thymalin is derived from bovine thymus; cross-reactivity is possible though not guaranteed. - **Pregnancy** — no safety data; avoid. - **Breastfeeding** — no safety data; avoid or discuss timing with obstetric provider. - **Active malignancy outside of oncology-integrated protocols** — not a standalone cancer treatment; immunomodulatory effects may be ambiguous in cancer contexts. - **Current solid organ transplant on immunosuppression** — antagonism with required immunosuppression; discuss with transplant team before any consideration. **Relative contraindications and use with caution:** - **Active autoimmune disease** — immunomodulatory effects may theoretically worsen autoimmunity; use only under rheumatology or immunology guidance. - **Active severe infection with immune compromise (e.g., active sepsis, acute HIV seroconversion)** — defer until acute phase resolved and clinical stability achieved. - **Known congenital immune deficiencies** — use only under immunology specialist supervision. - **Severe renal impairment** — limited data on peptide clearance in renal failure; dose adjustment may be prudent. - **Severe hepatic impairment** — limited pharmacokinetic data; use with caution. - **Pediatric population outside of Russian clinical supervision** — pediatric use is established in Russian clinical practice but should not be undertaken casually in Western settings. - **Concurrent immunosuppressive medications (cyclosporine, tacrolimus, corticosteroids ≥20 mg prednisone equivalent, biological DMARDs)** — antagonistic mechanisms; discuss with prescribing clinician. - **Concurrent checkpoint inhibitor cancer immunotherapy** — unclear interaction; generally avoid combining without oncology guidance. - **Known hypersensitivity to other peptide medications** — potential cross-reactivity; initiate with caution and low dose. - **Recent severe infection with incomplete immune recovery** — benefit may be meaningful but caution warranted; monitor for paradoxical worsening. **Special considerations:** - **Bovine tissue source considerations**: Thymalin is produced from calf/bovine thymus tissue. For users with religious, ethical, or allergic concerns about bovine products, this is a consideration. No effective synthetic equivalent of the full Thymalin mixture exists (though individual component peptides like Thymosin Alpha-1 are synthesized). Prion risk, while theoretical, has not been documented as a clinical problem with Thymalin specifically given the low-prion-content of thymus tissue and pharmacopeial manufacturing. - **Research-chemical market quality**: For Western users, the quality of the product obtained from research-chemical markets is the most practical safety concern. Prefer suppliers with documented chain of custody, COA/HPLC purity data, endotoxin testing, and reputable cold-chain shipping. - **Injection-related risks**: standard risks of any injected biological product including injection-site infection (mitigated by sterile technique), localized tissue reactions, and very rare systemic anaphylaxis. - **Monitoring during use**: the relatively brief course duration (10-14 days) and discrete cycle structure make long-term adverse event accumulation less concerning than with chronic daily dosing, but monitoring CBC with lymphocyte differential before and after each course is prudent. **When to seek medical attention:** - Signs of severe allergic reaction: facial/throat swelling, severe rash, difficulty breathing, hypotension — call emergency services - Persistent or worsening injection-site reaction (spreading redness, fever, pus) — evaluate for infection - Unexplained high fever, persistent fatigue worsening during a course, lymphadenopathy that persists >1 week after course completion - Any unusual rash, bleeding, or bruising - Worsening of any autoimmune condition during or after a course **When to discontinue:** - Allergic or anaphylactoid reaction of any severity - Persistent intolerable side effects - New diagnosis of autoimmune disease during use - Planned pregnancy or current pregnancy - No meaningful objective benefit after 2 full cycles (evaluate expectations and consider alternative approaches)
Additional Notes
Standard dosing by context:
- Beginner first course: 5 mg/day × 10 days, one course
- Standard adult course: 10 mg/day × 10 days, 1-2 courses per year
- Intensive/advanced course: 10-15 mg/day × 10-14 days, 2-4 courses per year
- Pediatric (Russian clinical only): weight-based, 0.1-0.2 mg/kg/day × 5-10 days under pediatric immunologist supervision
- Post-infectious recovery course: 10 mg/day × 10 days starting 1-2 weeks after acute resolution
- Pre-surgical optimization: 10 mg/day × 5-10 days completed 1-2 weeks before procedure
Route of administration:
- Intramuscular (IM): Russian clinical standard. Deltoid or gluteal injection. Ensure full absorption from muscle depot. Rotate injection sites to avoid tissue irritation.
- Subcutaneous (SC): Widely used in research-chemical community for self-administration. Abdomen (with umbilical avoidance), thigh, or upper outer arm. Slightly slower absorption than IM but clinically equivalent for most purposes.
- Intranasal (experimental, less common): Some Russian protocols have used intranasal administration of short thymic peptides; not the standard route for full Thymalin mixture.
- Oral: Not effective — peptides destroyed by GI proteases. Do not use orally.
Timing and frequency:
- Morning administration preferred to align with natural cortisol and immune rhythm
- Once-daily dosing throughout a 10-day course (the standard Russian protocol)
- Do not continuously dose beyond the 10-14 day courses — the Russian clinical framework is based on discrete courses with recovery intervals
- Inter-course interval: minimum 4-6 weeks, typically 3-6 months between Thymalin courses
Formulation and supply:
- Russian pharmaceutical Thymalin: 10 mg lyophilized powder in glass vials, manufactured by Samson Med or authorized manufacturers under Russian pharmacopeial standards. Highest quality product where accessible.
- Research-chemical peptide market Thymalin: Lyophilized peptide mixture from US, European, or Chinese peptide manufacturers. Quality varies dramatically. Look for suppliers with COA (certificate of analysis), HPLC purity data, endotoxin testing, and reasonable cold-chain shipping. Avoid the cheapest suppliers.
- Vial sizes: typically 10 mg, 20 mg, or 50 mg lyophilized. Single-vial courses or multi-vial packages available.
- Cost: Russian pharmaceutical product is inexpensive in its home market (~$5-10 per 10 mg vial) but unavailable in most Western markets. Research-chemical market prices $30-80 per 10 mg vial depending on supplier and quality.
Storage:
- Lyophilized product (unreconstituted): refrigerated (2-8°C) in original packaging. Stable for 12-24 months per manufacturer.
- Reconstituted product: refrigerated (2-8°C), use within 7 days ideally (bacteriostatic water preparation) or within 24 hours (sterile water or saline preparation).
- Do not freeze reconstituted product.
- Protect from light during storage and prior to injection.
- Inspect before use — solution should be clear or very slightly opalescent, colorless; discard if discolored, cloudy, or containing particles.
Cycling and duration strategy:
- Standard cycle: 10 days on, then 3-6 months off before next course
- Intensive period cycle: 10 days on, 4-6 weeks rest, 10 days on (double-course) — reserved for immune recovery from significant stressors
- Multi-peptide cycle: 10 days Thymalin → 2-4 week rest → 10 days Epithalon → 2-4 week rest → next Thymalin course in 3-6 months
- Avoid continuous dosing — not aligned with the evidence base and may cause diminishing returns
Bioavailability considerations:
IM and SC injection provide similar systemic exposure to the active peptides. Plasma half-life of individual peptides in the mixture is short (minutes to hours) but biological effects persist for weeks to months after a course. The 10-day-course-then-rest pattern reflects this pharmacodynamic profile.
Where to Buy Thymalin
Compare 1 listing across 1 vendor — from $59.00
Frequently Asked Questions
What is the recommended Thymalin dosage?
Dosage for Thymalin varies by protocol. Consult a qualified healthcare provider.
How often should I take Thymalin?
Administration frequency depends on the specific protocol. Consult current research literature.
Does Thymalin need to be cycled?
Cycling requirements depend on the protocol. Follow established research guidelines.
What are Thymalin side effects?
Thymalin has a substantial safety record spanning four decades of Russian clinical use across hundreds of thousands of patients, with a relatively clean side-effect profile compared to many immunomodulatory agents. **Common side effects (1-10% incidence in Russian clinical data):** - Mild injection site reactions (redness, tenderness, rare induration) - Transient low-grade fever (more common in elderly subjects in the first few days of a course) - Mild headache (transient, rarely requires discontinuation) - Fatigue in the first 1-3 days of a course (reflecting the immune activation) **Uncommon side effects (<1%):** - Allergic reactions (urticaria, angioedema — rare but possible given the biological origin of the preparation) - Lymphadenopathy (transient, reflecting lymphoid tissue activation) - Increased sweating - Muscle aches during the active treatment course - Rare reports of skin rash or flushing **Serious side effects (extremely rare but reported):** - Anaphylaxis (extremely rare; possible with any biologically-derived injected peptide) - Autoimmune flare (theoretical concern in predisposed individuals; rare in practice) - Allergic dermatitis progression (for those with documented prior hypersensitivity to bovine products) **Quality control and research-chemical market concerns.** The most significant Western-context safety concern with Thymalin is not the Russian pharmacopeial product itself but the research-chemical market quality of material sourced outside regulated channels. Issues include: - **Bacterial endotoxin contamination**: biologically-derived peptide preparations can carry endotoxin from the source tissue or from manufacturing if sterility is poor. Pharmacopeial Thymalin is tested for endotoxin; research-chemical sources may not be. - **Peptide composition variability**: the active peptide profile depends on extraction and fractionation methods; unregulated suppliers may produce Thymalin with substantially different composition from the Russian reference product. - **Contamination with other biological molecules**: prion risk from bovine tissue is theoretically present (though never documented as a clinical problem with Thymalin specifically); other bovine viral contamination is possible with poorly-manufactured product. - **Mislabeling**: some "Thymalin" products in the Western research-chemical market may be Thymosin Alpha-1 (different molecule) or empty/underdosed product. The Russian pharmaceutical product (Thymalin by Samson Med or authorized manufacturers) is tested to pharmacopeial standards. Research-chemical-market Thymalin in the US and EU is not. This is a real consideration for Western users. **Drug-drug interactions.** No clinically significant drug-drug interactions are described in the Russian literature at standard therapeutic doses. Thymalin is a peptide preparation with no CYP metabolism and minimal protein binding. Theoretical interactions: - **Immunosuppressive medications** (cyclosporine, tacrolimus, corticosteroids): immunomodulatory antagonism; use with caution in transplant patients and autoimmune patients on immunosuppression. - **Biological DMARDs** (rituximab, tocilizumab, TNF inhibitors): potential interactions with other immunomodulatory biologics; discuss with rheumatology provider. - **Checkpoint inhibitor cancer immunotherapy** (pembrolizumab, nivolumab, ipilimumab): unclear interaction; generally avoid combining without oncology guidance. - **Vaccines**: may enhance vaccine response (desirable for most) but theoretical interaction with live-attenuated vaccines in immunosuppressed patients. **Pregnancy and lactation.** Thymalin is not recommended during pregnancy due to absence of safety data, not due to documented harm. Russian prescribing guidance typically excludes pregnancy and lactation from the approved use contexts. Avoid in pregnancy and during breastfeeding. **Pediatric use.** Thymalin has been used in pediatric populations in Russian clinical practice for congenital immunodeficiencies and post-infectious immune support. Pediatric use outside of Russian clinical settings is unusual and should be supervised by a pediatric immunologist if considered. **Cautions specific to aging research-chemical users:** - **Source verification**: prefer suppliers with documented chain of custody from Russian pharmaceutical manufacturing when possible; recognize that research-chemical peptide markets have substantial quality variation. - **Storage**: injectable lyophilized peptides should be refrigerated; once reconstituted, use within days and refrigerate continuously. - **Administration technique**: IM or SC injection should use sterile technique; poor technique has caused most injection-site problems historically. - **Allergy screening**: in patients with known allergies to bovine products, beef allergy, or history of anaphylaxis to other biologicals, skin testing or cautious low-dose initiation is prudent. **Long-term safety.** Decades of Russian clinical use have not identified cumulative toxicity, organ damage, or increased cancer risk attributable to Thymalin. The population with the longest documented use — elderly Russians receiving biannual Thymalin courses for decades as part of Khavinson's long-term cohort trials — showed improved, not worsened, clinical outcomes versus untreated controls. This is reassuring regarding chronic use safety in the population for whom the drug was developed.
Where can I buy Thymalin?
Compare 1 listings from 1 vendor on our price comparison page — starting from $59.00.
Free 2026 Peptide Cheat Sheet — 50 pages, PDF
Dosing, reconstitution, stacks, half-lives, and vendor trust tiers. The reference we wish we had on day one.
